Tzvetelina T.
- Country
- Bulgaria
- Department
- N/A
Research Overview
- A Phase 3 Study to Compare the Efficacy and Safety of KAI-9531 Versus Semaglutide in Participants Living with Obesity Without Diabetes
- Phase 3 Double-Blind, Placebo-Controlled Study on the Efficacy and Safety of Plozasiran in Adults with Hypertriglyceridemia
- Phase 3 Double-Blind, Placebo-Controlled Trial Evaluating Plozasiran Efficacy and Safety in Adults with Severe Hypertriglyceridemia
Data & Insights
Has run more than one trial at 95 of 151 partner sites.
Specializations
Metabolic Disorders
This investigator specializes in treating patients with severe hypertriglyceridemia and related metabolic conditions. Their research activities focus on innovative therapeutic approaches for managing lipid disorders.
- Lipid Metabolism
- Triglyceride Management
- Cardiovascular Risk Factors
The investigator's work encompasses the evaluation of novel treatments for patients with elevated triglyceride levels.
Therapeutic Focus
Their clinical expertise centers on treating patients with various forms of hypertriglyceridemia, from moderate to severe presentations. The investigator explores new therapeutic options for managing these conditions.
- Lipid-Lowering Therapies
- Metabolic Disease Management
- Treatment Innovation
The research activities concentrate on advancing treatment options for patients with lipid disorders.
Clinical Interests
The investigator's clinical focus includes the study of serum triglyceride levels and their impact on patient health. Their work involves evaluating therapeutic interventions for metabolic disorders.
- Metabolic Biomarkers
- Lipid Profile Analysis
- Treatment Efficacy Assessment
Their research encompasses the evaluation of emerging therapies for lipid metabolism disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.